ISSN: 7027-2221

Keywords : Estradiol


CHARACTERIZATION OF INVASIVE DUCTAL CARCINOMA (IDC) IN PRE-AND POSTMENOPAUSAL WOMEN

KHALID MAHDI SALIH

karbala journal of pharmaceutical sciences, Volume 8, Issue 13, Pages 188-196

Background: Previous findings reported that the majority of BC in Iraqi women is invasive ductal carcinoma (IDC) and the most frequent subtype is estrogen receptor (ER+) and/or progesterone receptor (PR+) expressed.
Objective: The present study is aimed to determine the association of age, BMI, and the levels of estradiol and progesterone hormones as well as their receptors in pre- and postmenopausal women with IDC that may ultimately help identify high-risk women who would benefit from increased screening or chemoprevention.
Methodology: Forty premenopausal and fifty eight (58) postmenopausal women with IDC, previously identified their ER and PR expression, are involved in this study. Age, BMI, and serum levels of estradiol and progesterone are determined.
Results: Both pre- and postmenopausal patients are presented at advanced age (45.8 ± 0.76, 59.1 ± 0.72 year) respectively. The average of BMI in both groups is within overweight category, but without significant difference between pre- and postmenopausal patients (27.3 ± 045, and 26.7±0.38 kg/m2 respectively). Both estradiol and progesterone serum levels are significantly higher in premenopausal patients (290.1± 6.5 pg/ml, and 2.55± 0.38 ng/ml respectively) than those in postmenopausal patients (264.1± pg/ml, and 0.75± ng/ml respectively). Just postmenopausal patients showed significant reverse association between E2 levels and the positively expression of ER (r= - 0.289), and PR (r= - 0.386), while progesterone levels showed significant association with age of pre- and postmenopausal, and with BMI of postmenopausal.
Conclusion: Collectively, age, estradiol level, and expression of ER and PR are the main factors associated with the diversity of breast cancer in pre- and postmenopausal women and ultimately they may help in identifying high-risk women who would benefit from increased screening or chemoprevention.